## DVA: DaVita Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.12 indicates fundamental undervaluation. Quality metrics strong (ROE 62%).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($114.69)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Davita Inc. Appoints Stephanie Hendrickson as Chief People Officer and Steve Phillips as Chief Strategy Officer, Effective December 11, 2025**
- Source: marketscreener.com | 20251211T150813 | Bullish | Relevance: 98%
-  DaVita Inc. (NYSE: DVA) has announced the appointments of Stephanie Hendrickson as Chief People Officer and Steve Phillips as Chief Strategy Officer, effective December 11, 2025. Hendrickson, who joined DaVita in 2013, will focus on strengthening teams, while Phillips will expand his role to oversee DaVita Venture Group and corporate strategy. These appointments highlight DaVita's commitment to visionary leadership and driving innovation in healthcare to improve patient outcomes and foster a thriving culture.

**2. Amundi Cuts Stock Holdings in DaVita Inc. $DVA**
- Source: MarketBeat | 20251209T081111 | Neutral | Relevance: 98%
-  Amundi reduced its stake in DaVita Inc. by 11.5% in the second quarter, bringing its total holdings to 458,331 shares valued at approximately $65.34 million. Wall Street analysts maintain a cautious outlook on DaVita, with an average "Reduce" rating and a price target of $148. The company recently missed its quarterly EPS estimates, reporting $2.51 against an expected $3.17, while revenue was largely in line with forecasts.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 4 ($55.95M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 69.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Berkshire Hathaway, : 45.6% (-4.8%)
- Vanguard Group Inc: 6.0% (-10.9%)
- Blackrock Inc.: 5.1% (-13.1%)
- State Street Corpora: 2.6% (-12.4%)
- Invesco Ltd.: 2.4% (+2.0%)

### Key Risks

1. Heavy insider selling: $56M sold (4 transactions in 90 days).
2. High short interest (21.2%, 6.2 days to cover): squeeze risk or crowded bearish bet.
3. Long-term trend broken: trading 11.6% below SMA200.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.12 suggests fair value with growth premium. Forward P/E 9.4x attractive for 19% earnings growth. Quality metrics strong (ROE 62%). Insider selling cluster ($56.0M in 90 days), potential headwind. Institutional flow bearish (7 selling vs 3 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $8.6B |
| Beta | 0.99 |
| 52W Range | $113.97 - $179.60 |
| Short Interest | 21.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.12 |
| Forward P/E | 9.4 |
| Current P/E | 11.3 |
| YoY Growth | 19.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -4.0% to -0.8% (+3.2% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.8pp (needs >4.0% for momentum thesis). MRS_5 turning positive (1.9%) - potential reversal signal. Below SMA200 (0.88x), long-term trend not supportive. RSI neutral at 51.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.80% (CS: 41) | Neutral |
| RSI_14 | 51.0 | Neutral |
| MACD Histogram | 0.36 | Bullish |
| vs SMA20 | 1.014x | Above |
| vs SMA50 | 0.980x | Below |
| vs SMA200 | 0.884x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $120.33
- **Stop Loss:** $114.69 (4.7% risk)
- **Target:** $131.61 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 244
- **Position Value:** $29,360.52
- **Portfolio %:** 29.36%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-12 (Est: $3.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.17 | $2.51 | -20.9% |
| 2025Q2 | $2.75 | $2.95 | +7.3% |
| 2025Q1 | $2.02 | $2.00 | -0.9% |
| 2024Q4 | $2.13 | $2.24 | +5.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*